Oncoteq is a clinical stage oncology biotech focused on drug development powered by AI.
Headquartered in Cham, Switzerland, with a focus on innovative treatments for cancer, the company pipeline currently comprises three assets of first-in-class or best-in-class innovative therapeutic options in areas of high unmet need.
What we do
Oncoteq is a clinical stage biotechnology company focused on drug development within oncology.
Oncoteq leverages artificial intelligence to identify the optimal applications of a given molecule and de-risk clinical development.
Oncoteq est.
2022
Privately held
10+ Employees
Strategic partners
Innoplexus
Office in Cham
Founded, seeded by Cureteq AG
Latest news
Meeting at J.P. Morgan 2024?
Looking for partnering or investment with Oncoteq? CEO Mads Dalsgaard, CFO Swati Mehta, and CBO Sarah Holland will be attending so please reach out to set up meeting in San Francisco
Oncoteq completes another in-licensing deal, adding a potential best-in-class CD30 antibody drug conjugate from Tubulis to its oncology pipeline
Oncoteq AG (Oncoteq), a clinical stage biotech company specializing in novel and innovative cancer treatments, is expanding its development pipeline by in-licensing the potential best-in-class antibod …
Oncoteq expands pipeline with TEQ103 , a promising treatment for breast cancer
Today we announce the second in-licensing deal as we obtain a world-wide exclusive license to a novel compound with potential to shift the paradigm in breast cancer treatment. The first-in-class compo …
Shortcuts
About Us
Oncoteq is a clinical stage biotech, that leverages AI to unlock the value of exciting oncology assets
Pipeline
The Oncoteq pipeline currently comprises three assets focusing on oncology. Oncoteq
Platform
The Cureteq platform uniquely combines a fully flexible and agile biotech company-builder model with AI supported drug development
Transforming drug development
We aim to transform drug development and drive assets beyond value inflection points by:
- Unlocking hidden value of unattended molecules through AI
- Combining agility and expertise in a lean structure
- Flexibly partnering and financing assets